Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Introduction: We evaluated tissue tumor mutational burden (tTMB) and mutations in STK11, KEAP1, and KRAS as biomarkers for outcomes with pembrolizumab plus platinum-based chemotherapy (pembrolizumab-combination) for NSCLC among patients in the phase 3 KEYNOTE-189 (ClinicalTrials.gov, NCT02578680; no...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Marina C. Garassino, MD, Shirish Gadgeel, MD, Silvia Novello, MD, PhD, Balazs Halmos, MD, Enriqueta Felip, MD, Giovanna Speranza, MD, Rina Hui, PhD, Edward B. Garon, MD, Hidehito Horinouchi, MD, PhD, Shunichi Sugawara, MD, PhD, Delvys Rodriguez-Abreu, MD, PhD, Martin Reck, MD, Razvan Cristescu, PhD, Deepti Aurora-Garg, PhD, Andrey Loboda, PhD, Jared Lunceford, PhD, Julie Kobie, PhD, Mark Ayers, MS, Bilal Piperdi, MD, M. Catherine Pietanza, MD, Luis Paz-Ares, MD, PhD
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Elsevier 2023-01-01
Серія:	JTO Clinical and Research Reports
Предмети:	Tissue tumor mutational burden Single-gene genetic alterations Pembrolizumab Metastatic non‒small-cell lung cancer Biomarker
Онлайн доступ:	http://www.sciencedirect.com/science/article/pii/S2666364322001552
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Схожі ресурси